scispace - formally typeset
J

Jungwoo Kim

Researcher at California Institute of Technology

Publications -  26
Citations -  1964

Jungwoo Kim is an academic researcher from California Institute of Technology. The author has contributed to research in topics: Medicine & T cell. The author has an hindex of 10, co-authored 18 publications receiving 1555 citations. Previous affiliations of Jungwoo Kim include Cornell University.

Papers
More filters
Journal ArticleDOI

Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase.

TL;DR: It is found that Sirt5 is an efficient protein lysine desuccinylase and demalonylase in vitro and may represent a posttranslational modification that can be reversed by Sirt 5 in vivo.
Journal ArticleDOI

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.

TL;DR: Biophysical insights are provided into how BRAF mutant melanoma cells adapt to the stress of MAPK inhibition via a series of reversible phenotypic transitions toward drug-tolerant or drug-resistant cell states enriched for neural-crest factors and mesenchymal signatures.
Journal ArticleDOI

Gene-targeted microfluidic cultivation validated by isolation of a gut bacterium listed in Human Microbiome Project's Most Wanted taxa

TL;DR: Isolate microfluidicus 1 is, to the authors' knowledge, the first successful example of targeted cultivation of a microorganism from the high-priority group of the Human Microbiome Project’s “Most Wanted” list, and the first cultured representative of a previously unidentified genus of the Ruminococcaceae family.
Journal ArticleDOI

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

TL;DR: Although buparlisib achieved significant brain penetration, the lack of clinical efficacy was explained by incomplete blockade of the PI3K pathway in tumor tissue, and integrative results suggest that additional study ofPI3K inhibitors that achieve more-complete pathway inhibition may still be warranted.